Skip to main content
Top
Published in: Clinical Rheumatology 3/2011

01-03-2011 | Original Article

Fifteen-year trends of long-term disability and sick leaves in ankylosing spondylitis

Authors: Cesar Ramos-Remus, Guillermo Hernandez-Rios, Sergio Duran-Barragan, Adriana Sanchez-Ortiz, Francisco Javier Aceves-Avila, Jose Dionisio Castillo-Ortiz, Oscar Gonzalez-Perez

Published in: Clinical Rheumatology | Issue 3/2011

Login to get access

Abstract

The aim of this study is to assess the trends in work disability and sick leave in ankylosing spondylitis (AS). In 1993 and 2007, patients diagnosed with AS that attended to a secondary- or a tertiary-care outpatient rheumatology clinics were evaluated for demographics, disease characteristics, axial mobility, working status, and work days missed due to sick leave or permanent disability. Factors that impacted labor status were identified by multiple regression analysis. In 1993, 91 study individuals (mean age 35 years, mean disease duration 10 ± 8 years) included 28 (31%) on permanent disability and 63 currently working; of these 63, 42 (67%) had missed at least 1 work day in the previous 12 months (mean 69 ± 63 days). In the next 5 years, the annual permanent disability was 3%. In 2007, 185 study individuals (mean age 42, mean disease duration 12 ± 10 years) included 53 (39%) on permanent disability and 132 active workers; 35 (66%) out of the 53 began permanent disability between 1999 and 2007 (2.1% annual disability rate), and 53 (40%) out of 132 active workers missed at least 1 work day in the previous 12 months (mean 52 ± 63 days). Only age predicted disability, with 10% and 11% increases in risk per year in 1993 and 2007, respectively (hazard ratios 1.09 and 1.11, respectively; p = 0.03 for both). Although the impact of AS on work seems to decrease slightly during the last 15 years, the actual impact is still substantial. An important proportion of patients went on permanent disability in the three decades before retirement. Extrapolating these results to official data for the year 2005, we may infer that between 1.3 million and nearly 15 million working days were missed that year due to AS.
Literature
1.
go back to reference Gran JT, Husby G (1993) The epidemiology of ankylosing spondylitis. Semin Arthritis Rheum 22:319–334PubMedCrossRef Gran JT, Husby G (1993) The epidemiology of ankylosing spondylitis. Semin Arthritis Rheum 22:319–334PubMedCrossRef
2.
go back to reference Gran JT, Skomsvoll JF (1997) The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 36:766–771PubMedCrossRef Gran JT, Skomsvoll JF (1997) The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 36:766–771PubMedCrossRef
3.
go back to reference Rkain H, Allali F, Bentalha A et al (2007) Socioeconomic impact of ankylosing spondylitis in Morocco. Clin Rheumatol 26:2081–2088PubMedCrossRef Rkain H, Allali F, Bentalha A et al (2007) Socioeconomic impact of ankylosing spondylitis in Morocco. Clin Rheumatol 26:2081–2088PubMedCrossRef
4.
go back to reference Boonen A, Severens JL (2002) Ankylosing spondylitis: what is the cost to society, and can it be reduced? Best Pract Res Clin Rheumatol 16:691–705PubMedCrossRef Boonen A, Severens JL (2002) Ankylosing spondylitis: what is the cost to society, and can it be reduced? Best Pract Res Clin Rheumatol 16:691–705PubMedCrossRef
5.
go back to reference Boonen A, Chorus A, Miedema H et al (2001) Withdrawal from labour force due to work disability in patients with ankylosing spondylitis. Ann Rheum Dis 60:1033–1039PubMedCrossRef Boonen A, Chorus A, Miedema H et al (2001) Withdrawal from labour force due to work disability in patients with ankylosing spondylitis. Ann Rheum Dis 60:1033–1039PubMedCrossRef
6.
go back to reference Strombeck B, Jacobsson LT, Bremander A et al (2009) Patients with ankylosing spondylitis have increased sick leave—a registry-based case–control study over 7 years. Rheumatol (Oxford) 48:289–292CrossRef Strombeck B, Jacobsson LT, Bremander A et al (2009) Patients with ankylosing spondylitis have increased sick leave—a registry-based case–control study over 7 years. Rheumatol (Oxford) 48:289–292CrossRef
7.
go back to reference Boonen A, Chorus A, Miedema H et al (2001) Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 60:353–358PubMedCrossRef Boonen A, Chorus A, Miedema H et al (2001) Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 60:353–358PubMedCrossRef
8.
go back to reference Mau W, Listing J, Huscher D et al (2005) Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J Rheumatol 32:721–728PubMed Mau W, Listing J, Huscher D et al (2005) Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J Rheumatol 32:721–728PubMed
9.
go back to reference Khan MA (1990) Ankylosing spondylitis: clinical aspects. In: Khan MA (ed) Ankylosing spondylitis and related spondyloarthropathies. Hanley & Belfus, Philadelphia, pp 529–551 Khan MA (1990) Ankylosing spondylitis: clinical aspects. In: Khan MA (ed) Ankylosing spondylitis and related spondyloarthropathies. Hanley & Belfus, Philadelphia, pp 529–551
10.
go back to reference Ramos-Remus C, Macias MA, Suarez-Almazor ME (1997) Labor status and working-days lost in a consecutive sample of 103 patients with ankylosing spondylitis. Arthritis Rheum 40(supplement):1392 Ramos-Remus C, Macias MA, Suarez-Almazor ME (1997) Labor status and working-days lost in a consecutive sample of 103 patients with ankylosing spondylitis. Arthritis Rheum 40(supplement):1392
11.
go back to reference Jenkinson TR, Mallorie PA, Whitelock HC et al (1994) Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 21:1694–1698PubMed Jenkinson TR, Mallorie PA, Whitelock HC et al (1994) Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 21:1694–1698PubMed
12.
go back to reference Garrett S, Jenkinson T, Kennedy LG et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291PubMed Garrett S, Jenkinson T, Kennedy LG et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291PubMed
13.
go back to reference Calin A, Jones SD, Garrett SL et al (1995) Bath ankylosing spondylitis functional index. Br J Rheumatol 34:793–794PubMedCrossRef Calin A, Jones SD, Garrett SL et al (1995) Bath ankylosing spondylitis functional index. Br J Rheumatol 34:793–794PubMedCrossRef
14.
go back to reference Daltroy LH, Larson MG, Roberts NW et al (1990) A modification of the health assessment questionnaire for the spondyloarthropathies. J Rheumatol 17:946–950PubMed Daltroy LH, Larson MG, Roberts NW et al (1990) A modification of the health assessment questionnaire for the spondyloarthropathies. J Rheumatol 17:946–950PubMed
15.
go back to reference van der Linden SM (1990) Clinical and functional assessment of ankylosing spondylitis. In: Khan MA (ed) Ankylosing spondylitis and related spondyloarthropathies. Hanley & Belfus, Philadelphia, pp 583–593 van der Linden SM (1990) Clinical and functional assessment of ankylosing spondylitis. In: Khan MA (ed) Ankylosing spondylitis and related spondyloarthropathies. Hanley & Belfus, Philadelphia, pp 583–593
16.
go back to reference Boonen A, van der Linden SM (2006) The burden of ankylosing spondylitis. J Rheumatol Suppl 78:4–11PubMed Boonen A, van der Linden SM (2006) The burden of ankylosing spondylitis. J Rheumatol Suppl 78:4–11PubMed
17.
go back to reference Forejtova S, Mann H, Stolfa J et al (2008) Factors influencing health status and disability of patients with ankylosing spondylitis in the Czech Republic. Clin Rheumatol 27:1005–1013PubMedCrossRef Forejtova S, Mann H, Stolfa J et al (2008) Factors influencing health status and disability of patients with ankylosing spondylitis in the Czech Republic. Clin Rheumatol 27:1005–1013PubMedCrossRef
18.
go back to reference Zhu TY, Tam LS, Lee VW et al (2008) Costs and quality of life of patients with ankylosing spondylitis in Hong Kong. Rheumatol (Oxford) 47:1422–1425CrossRef Zhu TY, Tam LS, Lee VW et al (2008) Costs and quality of life of patients with ankylosing spondylitis in Hong Kong. Rheumatol (Oxford) 47:1422–1425CrossRef
19.
go back to reference Boonen A, Brinkhuizen T, Landewe R et al (2010) Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. Ann Rheum Dis 69:1123–1128PubMedCrossRef Boonen A, Brinkhuizen T, Landewe R et al (2010) Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. Ann Rheum Dis 69:1123–1128PubMedCrossRef
20.
go back to reference Braun J, Bollow M, Remlinger G et al (1998) Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 41:58–67PubMedCrossRef Braun J, Bollow M, Remlinger G et al (1998) Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 41:58–67PubMedCrossRef
21.
go back to reference Zink A, Braun J, Listing J et al (2000) Disability and handicap in rheumatoid arthritis and ankylosing spondylitis—results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 27:613–622PubMed Zink A, Braun J, Listing J et al (2000) Disability and handicap in rheumatoid arthritis and ankylosing spondylitis—results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 27:613–622PubMed
22.
go back to reference Verstappen SM, Jacobs JW, van der Heijde DM et al (2007) Utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritis. Ann Rheum Dis 66:727–731PubMedCrossRef Verstappen SM, Jacobs JW, van der Heijde DM et al (2007) Utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritis. Ann Rheum Dis 66:727–731PubMedCrossRef
23.
go back to reference Duijts SF, Kant I, Swaen GM et al (2007) A meta-analysis of observational studies identifies predictors of sickness absence. J Clin Epidemiol 60:1105–1115PubMedCrossRef Duijts SF, Kant I, Swaen GM et al (2007) A meta-analysis of observational studies identifies predictors of sickness absence. J Clin Epidemiol 60:1105–1115PubMedCrossRef
24.
go back to reference Chorus AM, Miedema HS, Boonen A et al (2003) Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann Rheum Dis 62:1178–1184PubMedCrossRef Chorus AM, Miedema HS, Boonen A et al (2003) Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann Rheum Dis 62:1178–1184PubMedCrossRef
25.
go back to reference Suarez-Almazor ME (2002) In quest of the holy grail: efficacy versus effectiveness in rheumatoid arthritis. J Rheumatol 29:209–211PubMed Suarez-Almazor ME (2002) In quest of the holy grail: efficacy versus effectiveness in rheumatoid arthritis. J Rheumatol 29:209–211PubMed
Metadata
Title
Fifteen-year trends of long-term disability and sick leaves in ankylosing spondylitis
Authors
Cesar Ramos-Remus
Guillermo Hernandez-Rios
Sergio Duran-Barragan
Adriana Sanchez-Ortiz
Francisco Javier Aceves-Avila
Jose Dionisio Castillo-Ortiz
Oscar Gonzalez-Perez
Publication date
01-03-2011
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 3/2011
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-010-1669-y

Other articles of this Issue 3/2011

Clinical Rheumatology 3/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine